Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Company to Host Financial Results Conference Call and Update on Business Developments on Thursday, April 25, 2019, at 4:15 p.m. ET DENVER, April 17, 2019 — Medicine Man Technologies, Inc. (otcqx:MDCL) (“Medicine Man Technologies” or “Company”), […]
– SAFE Banking Act would provide cannabis companies access to banking services that all other legal businesses have- American cannabis companies would be on more equal footing with Canadian cannabis peers with access to depository […]
– This group of four dispensaries is expected to have EBITDA margins of 35% in 2019 and will be among the most profitable retail locations in the Company’s portfolio, upon transaction closing- Company is now […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
